This study demonstrated that tumor cells with high EZH2 expression were not sensitive to PARPi treatment, and in patient-derived xenografts, EZH2 inhibitors sensitize CARM1-high OCs to PARPi (Karakashev et al., 2020). This evidence concerns the gene EZH2 and neoplasm.